Search
Grandpharm-Sinovac's Recombinant Zoster Vaccine Wins FDA Approval for Clinical Trials in the U.S.
5 day ago /
Read about 0 minute
Author：小编
Grandpharm-Sinovac Life Sciences (Nanjing) Co., Ltd. has submitted its self-developed recombinant zoster vaccine (not a varicella vaccine) for clinical trials in China, and the application has been accepted for review. Furthermore, the vaccine has garnered approval to commence clinical research in Australia. Leveraging recombinant protein technology in tandem with the proprietary TVA01 adjuvant system, this vaccine is devoid of viral components, promising enhanced safety and a reduced incidence of adverse reactions. It boasts superior safety profile when compared to live attenuated vaccines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
